Table 2.
Hemodynamic Safety Markers
| 300 mg | 600 mg | |||||||||
| Week | 0 | 1 | 3 | 8 | 11 | 0 | 1 | 3 | 8 | 11 |
| Heart Rate (bpm) | 64 ± 7.6 | 58 ± 4.7 | 61 ± 5.1 | 61 ± 5.6 | 64 ± 8.7 | 57 ± 6.2 | 58 ± 6.7 | 59 ± 7.2 | 61 ± 3.0 | 64 ± 8.6 |
| SBP (mmHg) | 116 ± 13.0* | 114 ± 9.8* | 117 ± 12.3* | 117 ± 10.7* | 116 ± 8.8* | 75 ± 8.7 | 74 ± 9.3 | 73 ± 8.1 | 70 ± 7.9 | 77 ± 5.6 |
| BBP (mmHg) | 109 ± 6.4 | 107 ± 5.2 | 113 ± 6.9 | 115 ± 11.4 | 114 ± 4.8 | 69 ± 8.2 | 74 ± 4.5 | 71 ± 9.4 | 76 ± 9.9 | 74 ± 6.3 |
* Denotes significant main effects for groups (p < 0.05). Results indicated that the 300 mg group had significant higher baseline values that persisted throughout the study, and was apparently independent of 6-OXO supplementation.